65,437 trials
Aplastic Anemia
Primary: Patients Treated With Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) Achieving at Least a Partial Remission (PR) at 6 Months — 9 participants
Alcohol Withdrawal
Primary: Number of Patients Requiring Continuous Lorazepam Infusion — 2; 16 participants
Diabetes Mellitus, Type 2
Primary: Frequency of Patients With Adverse Events (AEs) — 1253; 465; 57; 23 Participants
Hereditary Angioedema
Primary: Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the…
Respiratory Infection · Gastroenteritis
Primary: Cumulative Number of Reported Days-off Episodes in the Arm Due to Own Infectious Disease Over the Total Number of Follow-up Weeks in the Arm — 625; 418; 405 sick-leave…
Type 2 Diabetes
Primary: Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c) — 7.90; 7.94; 7.10; 7.55 percent — p=<0.0001
Coronary Restenosis
Primary: Phase I: Number of Participants With Dose-limiting Toxicities — 0; 0; 0; 0 participants
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 4.90 Months
Overweight · Obesity
Primary: Change in Body Weight From Baseline to 12 Months — -5.7; -6.4 kg
Essential Hypertension
Primary: Systolic Blood Pressure Measured by Tested Device. — 144.11 mmHg
Atherosclerosis · Coronary Artery Disease
Primary: Cardiac Events (Composite) — 1.0 percentage of participants
Pulmonary Disease, Chronic Obstructive
Primary: Mean Number of Pharmacy Claims by Participants During the Post-Index Period — 2.960; 0.219; 5.491; 0.573 pharmacy claims
Hyponatremia
Primary: Serum Sodium Levels in Both Groups — 137.8; 140.0 mEq/L — p=0.04
Lipid Metabolism Disorder
Primary: Number of Participants With Lipid Panel Control — 249; 192; 245; 231 participants
Breast Cancer
Primary: Clinical Response — 3; 30; 11; 3 participants